Grail's Slump Enters Week: Navigating Biotech's Setback
Grail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...
This comparison outlines 2024 tax treatment differences between dividends from ETFs and mutual funds for informed decisions.
24,763 articlesGrail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...
Investors are buzzing about a possible SpaceX-Tesla merger. This guide explains the real possibilities, benefits, ris...
Celsius founder Alex Mashinsky has filed to vacate a 12-year crypto fraud sentence, signaling a dramatic turn in a ca...
TG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
As Seer gears up for 2025 earnings, investors weigh growth, margins, and risk. This guide breaks down the drivers beh...
Pet owners are delaying routine vet visits to save money, yet expensive emergency surgeries keep pet-health firms in ...
As markets hit new highs, investors wonder what happens if political pressure reshapes central-bank policy. This arti...
Markets paused to digest a major memory-chip move while the Nasdaq Composite held steady. This article breaks down wh...
Bank-owned properties are climbing fast. This guide explains why the 25.7% increase matters, how it reshapes pricing ...
The S&P 500 has slipped this year, yet three tech-focused ETFs powering AI names have kept a higher trajectory over t...
Vanguard’s mid-cap ETF VO is drawing renewed attention as markets tilt toward diversification beyond mega-cap tech. T...
Investors are watching the Fed for its next move, a key factor in whether GLD can extend its recent 36% rally. Real y...